NeuroPulse Daily: January 05, 2026
Daily neurology update covering Alzheimer’s, Parkinson’s, epilepsy, ADHD.
News
NICE Clears MS Treatment Option Suitable During Pregnancy
NICE backs natalizumab for highly active relapsing MS.
NICE Backs Age-Based Blood Test to Spot Ovarian Cancer
NICE proposes age-based CA125 testing to improve early diagnosis.
Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
Germany Updates Meningococcal, Shingles Vaccine Policy for 2026
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
EU Finalizes Landmark Pharma Reform to Reset Access and Incentives
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
NeuroPulse Today’s Signals: Personalized Neuromodulation, Pediatric Imaging Wins, and Schizophrenia IP Resets
NeuroPulse: Today’s Three Signals The neurology sector delivered three distinct signals today, spanning device-led personalization, regulatory expansion in pediatric imaging, and strategic recalibration in neuropsychiatric drug development. Together, they highlight how execution, not novelty, is increasingly determining momentum across neuroscience. Signal One: Soin Neuroscience and BIOTRONIK Push Spinal Cord Stimulation Toward Personalization Soin Neuroscience and … Read more
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.
NeuroPulse Daily Brief: December 20, 2025
In Today’s NeuroPulse, the neurology sector advanced across multiple fronts, with fresh capital flowing into mental health drug development, early clinical milestones reached in brain cancer and neurodegeneration, and regulators extending approvals that lower risk in pediatric imaging and neuromodulation. From nine-figure biotech launches and oversubscribed neurotech seed rounds to first-in-human dosing, personalized spinal cord … Read more